Prevalence and Impact in Work Productivity of Gastroesophageal Reflux Disease (GERD) in Primary Care Patients With Upper Gastrointestinal (GI) Symptoms Using GerdQ
GerdQ-Greece
A Cross-sectional Study on the Prevalence and Impact in Work Productivity of GERD in Primary Care Patients With Upper GI Symptoms Using the Novel Questionnaire GERD-Q. The Greek GERD-Q Study
1 other identifier
observational
889
1 country
54
Brief Summary
The purpose of the study is to provide data on the GERD prevalence as percentage of patients with upper GI symptoms that are identified with GERD using the GerdQ Questionnaire. Furthermore the study aims to estimate GERD prevalence in patients based on their symptoms as they respond to a physician's questionnaire, to observe possible variations between the two methods (physicians' symptom rating and GerdQ), to objectively measure treatment response and to identify the percentage of patients that may require alterations of their treatment. Finally, to describe the impact of GERD symptoms on work productivity.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2009
Shorter than P25 for all trials
54 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 3, 2009
CompletedFirst Posted
Study publicly available on registry
June 5, 2009
CompletedStudy Start
First participant enrolled
July 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2009
CompletedDecember 29, 2009
December 1, 2009
June 3, 2009
December 24, 2009
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
GERD prevalence as percentage of patients with upper GI symptoms that are identified with GERD using the GerdQ Questionnaire (GerdQ score >=8).
Single Visit - once
Secondary Outcomes (3)
Estimation of GERD prevalence in patients based on their symptoms as they respond to a physician's questionnaire and to observe possible variations between the two methods (physicians' symptom rating and QerdQ)
Single Visit - Once
Describe the impact of GERD symptoms on work productivity.
Single Visit - Once
To objectively measure treatment response and to identify the percentage of patients that may require alterations of their treatment.
Single Visit - Once
Study Arms (1)
Upper-GI symptoms in primary-care patients
Eligibility Criteria
Patients who consult their primary care physician and have experienced upper-GI symptoms during the last week prior their consultation
You may qualify if:
- Patients with upper-GI symptoms the last week prior visiting the investigator
You may not qualify if:
- History of oesophageal, gastric or duodenal surgery
- Treatment with NSAIDs/Acetylsalicylic acid within the last week prior to the study visit
- PPI use for healing of NSAIDs induced ulcer or for HP eradication
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (54)
Research Site
Pátrai, Achaias, Greece
Research Site
Mesologgion, Aitoloakarnaniaia, Greece
Research Site
Naupaktos, Aitoloakarnaniaia, Greece
Research Site
Grinion, Aitoloakarnania, Greece
Research Site
Aleksandroupoli, Aleksandroupoli, Greece
Research Site
Tripoli, Arkadias, Greece
Research Site
Acharnes, Attica, Greece
Research Site
Ag.Eleutherios, Attica, Greece
Research Site
Ag.Paraskeui, Attica, Greece
Research Site
Artémida, Attica, Greece
Research Site
Athens, Attica, Greece
Research Site
Chalandri, Attica, Greece
Research Site
Galatsi, Attica, Greece
Research Site
Glifada, Attica, Greece
Research Site
Ilipoli, Attica, Greece
Research Site
Kallithea, Attica, Greece
Research Site
Keratea, Attica, Greece
Research Site
Marousi, Attica, Greece
Research Site
N Makri, Attica, Greece
Research Site
N Smirni, Attica, Greece
Research Site
N.Herakeleios, Attica, Greece
Research Site
Peristeri, Attica, Greece
Research Site
Pikermi, Attica, Greece
Research Site
Pikerni, Attica, Greece
Research Site
Spata, Attica, Greece
Research Site
Chalcis, Chalkida, Greece
Research Site
Chalkidiki, Chalkidiki, Greece
Research Site
Chania, Chania, Greece
Research Site
Corinth, Corinth, Greece
Research Site
Mykonos, Cyclades, Greece
Research Site
Santorini, Cyclades, Greece
Research Site
Drama, Drama, Greece
Research Site
Zakynthos, Eptanisa, Greece
Research Site
Lamia, Ftiotida, Greece
Research Site
Heraklion, Herakleion, Greece
Research Site
Lexena, Ilias, Greece
Research Site
Véroia, Imathias, Greece
Research Site
Ioannina, Ioannina, Greece
Research Site
Karditsa, Karditsa, Greece
Research Site
Kastoria, Kastoria, Greece
Research Site
Katerini, Katerini, Greece
Research Site
Chrisoupoli, Kavala, Greece
Research Site
Komotini, Komotini, Greece
Research Site
Lakonia, Lakonia, Greece
Research Site
Larrisa, Larrisa, Greece
Research Site
Volos, Magnisia, Greece
Research Site
Kalamata, Mesinia, Greece
Research Site
Giannitsá, Pella, Greece
Research Site
Pereus, Pereus, Greece
Research Site
Ptolemaida, Ptolemaida, Greece
Research Site
Thessaloniki, Salonika, Greece
Research Site
Serres, Serres, Greece
Research Site
Trikala, Trikala, Greece
Research Site
Xánthi, Xanthi, Greece
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Theodoros Rokkas, Dr
Henry Dynan Hospital, Athens, Greece
- STUDY DIRECTOR
Panagiotis Pontikis, Dr
AstraZeneca Greece
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
June 3, 2009
First Posted
June 5, 2009
Study Start
July 1, 2009
Study Completion
December 1, 2009
Last Updated
December 29, 2009
Record last verified: 2009-12